Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
暂无分享,去创建一个
G. Halliday | N. Hattori | S. Sardi | T. Nakazato | W. Kim | H. Yoshino | H. Mochizuki | P. Lee | K. Kanai | S. Sekimoto | M. Funayama | Seung-Jae Lee | M. Ueyama | Yuanzhe Li | K. Nishioka | Dong-kyu Kim | Y. Nagai | M. Nakatani | H. S. Yoo | Jun Sung Lee | Byung Chul Jung | S. Kubo | Mari Suzuki | Minsun Choi | He‐Jin Lee | YuHong Fu | K. Oh | Ryusuke Sakai | Tomoko Nakazato | H. S. Yoo
[1] N. Hattori,et al. COQ2 variants in Parkinson’s disease and multiple system atrophy , 2018, Journal of Neural Transmission.
[2] E. Masliah,et al. Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril , 2016, Scientific Reports.
[3] Y. Shim,et al. Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function , 2016, Autophagy.
[4] K. Wada,et al. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. , 2015, Human molecular genetics.
[5] W. Chung,et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. , 2015, Brain : a journal of neurology.
[6] O. Brüstle,et al. Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[7] Kengo Kinoshita,et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals , 2015, Nature Communications.
[8] K. Ohno,et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study , 2015, The Lancet Neurology.
[9] E. Masliah,et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein , 2014, Nature Communications.
[10] Yoav Ben-Shlomo,et al. Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis , 2014, Journal of Parkinson's disease.
[11] He-Jin Lee,et al. Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases , 2014, Nature Reviews Neurology.
[12] J. Nutt,et al. Parkinsonism syndrome in heterozygotes for Niemann–Pick C1 , 2013, Journal of the Neurological Sciences.
[13] H. Liany,et al. A rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease , 2013, Neurobiology of Aging.
[14] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[15] He-Jin Lee,et al. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases , 2013, Biological chemistry.
[16] A. Mirelman,et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease , 2013, Neurology.
[17] N. Hattori,et al. VPS35 mutation in Japanese patients with typical Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[18] M. Prata,et al. Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. , 2012, Molecular genetics and metabolism.
[19] Dae Hyuk Moon,et al. Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.
[20] M. Ban,et al. Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome , 2012, Movement disorders : official journal of the Movement Disorder Society.
[21] T. Cox,et al. The cellular pathology of lysosomal diseases , 2012, The Journal of pathology.
[22] T. Outeiro,et al. Zooming into protein oligomerization in neurodegeneration using BiFC. , 2010, Trends in biochemical sciences.
[23] N. Hattori,et al. No evidence for pathogenic role of GIGYF2 mutation in Parkinson disease in Japanese patients , 2010, Neuroscience Letters.
[24] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[25] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[26] P. Taschner,et al. Caenorhabditis elegans as a model for lysosomal storage disorders. , 2008, Biochimica et biophysica acta.
[27] Nir Giladi,et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2008, Neurology.
[28] Y. Hirayasu,et al. Neuronal and glial accumulation of α- and β-synucleins in human lipidoses , 2007, Acta Neuropathologica.
[29] T. Noda,et al. Dissection of the Autophagosome Maturation Process by a Novel Reporter Protein, Tandem Fluorescent-Tagged LC3 , 2007, Autophagy.
[30] J. Aharon-Peretz,et al. Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype–genotype correlation , 2005, Neurology.
[31] Peter T. Lansbury,et al. Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.
[32] J. Allman,et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.
[33] He-Jin Lee,et al. Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.
[34] Jeremy N. Skepper,et al. α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.
[35] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[36] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[37] Y. Ihara,et al. Accumulation and Aggregation of Amyloid β-Protein in Late Endosomes of Niemann-Pick Type C Cells* , 2001, The Journal of Biological Chemistry.
[38] T. Chase,et al. Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.
[39] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[40] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[41] K. von Figura,et al. Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[42] L. Warren. Stimulated secretion of lysosomal enzymes by cells in culture. , 1989, The Journal of biological chemistry.
[43] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[44] R. Brady,et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. , 1966, The Journal of clinical investigation.
[45] N. Hattori,et al. Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. , 2013, Parkinsonism & related disorders.
[46] A. Harris,et al. Identification of seven novel mutations associated with metachromatic leukodystrophy , 1995, Human mutation.
[47] A. Allison,et al. The secretion of lysosomal enzymes. , 1976, Frontiers of biology.